Quince Therapeutics (QNCX) Institutional Ownership $1.08 -0.02 (-1.82%) Closing price 04:00 PM EasternExtended Trading$1.08 0.00 (0.00%) As of 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Quince Therapeutics (NASDAQ:QNCX)CurrentInstitutional OwnershipPercentage30.75%Number ofInstitutional Buyers(last 12 months)8TotalInstitutional Inflows(last 12 months)$749.06KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$27.15K Get QNCX Insider Trade Alerts Want to know when executives and insiders are buying or selling Quince Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data QNCX Institutional Buying and Selling by Quarter Quince Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails4/11/2025 Intellectus Partners LLC53,312$71K0.0%N/A0.121% 2/17/2025Two Sigma Investments LP30,341$57K0.0%N/A0.069% 2/17/2025Shay Capital LLC276,799$518K0.1%+60.8%0.629% 2/14/2025Northern Trust Corp50,524$94K0.0%+48.5%0.115% 2/12/2025Geode Capital Management LLC375,932$703K0.0%+10.9%0.854% 2/11/2025Virtu Financial LLC29,204$55K0.0%N/A0.066% 2/5/2025Anfield Capital Management LLC26,656$50K0.0%N/A0.061% 1/24/2025 Scharf Investments LLC91,061$170K0.0%N/A0.207% 11/16/2024Geode Capital Management LLC339,125$263K0.0%+24.2%0.784% 8/9/2024Renaissance Technologies LLC483,902$363K0.0%-7.0%1.120% 1/12/2024 Scharf Investments LLC91,061$96K0.0%N/A0.212% 7/31/2023 Intellectus Partners LLC53,527$81K0.0%N/A0.148% 7/24/2023BML Capital Management LLC1,411,839$2.13M1.9%N/A3.892% 5/11/2023EPIQ Capital Group LLC958,469$1.50M0.8%-9.3%2.642% 4/20/2023 Hennion & Walsh Asset Management Inc.31,061$48K0.0%N/A0.086% (Data available from 1/1/2016 forward) QNCX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of QNCX shares? During the previous two years, 11 institutional investors and hedge funds held shares of Quince Therapeutics. The most heavily invested institutionals were BML Capital Management LLC ($2.13M), EPIQ Capital Group LLC ($1.50M), Geode Capital Management LLC ($703K), Shay Capital LLC ($518K), Renaissance Technologies LLC ($363K), Scharf Investments LLC ($170K), and Northern Trust Corp ($94K).Learn more on QNCX's institutional investors. What percentage of Quince Therapeutics stock is owned by institutional investors? 30.75% of Quince Therapeutics stock is owned by institutional investors. Learn more on QNCX's institutional investor holdings. Which institutional investors have been buying Quince Therapeutics stock? Of the 9 institutional investors that purchased Quince Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: BML Capital Management LLC ($1.41M), Scharf Investments LLC ($182.12K), Intellectus Partners LLC ($106.84K), Shay Capital LLC ($104.62K), Geode Capital Management LLC ($102.98K), Two Sigma Investments LP ($30.34K), and Virtu Financial LLC ($29.20K). How much institutional buying is happening at Quince Therapeutics? Institutional investors have bought a total of 2,011,095 shares in the last 24 months. This purchase volume represents approximately $3.05M in transactions. Which Quince Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Quince Therapeutics stock in the last 24 months: EPIQ Capital Group LLC ($97.72K), and Renaissance Technologies LLC ($36.20K). How much institutional selling is happening at Quince Therapeutics? Institutional investors have sold a total of 133,920 shares in the last 24 months. This volume of shares sold represents approximately $179.59K in transactions. Related Companies Gossamer Bio Major Shareholders DiaMedica Therapeutics Major Shareholders Inventiva Major Shareholders MediWound Major Shareholders Eledon Pharmaceuticals Major Shareholders Cardiff Oncology Major Shareholders Voyager Therapeutics Major Shareholders Alumis Major Shareholders Fulcrum Therapeutics Major Shareholders Y-mAbs Therapeutics Major Shareholders This page (NASDAQ:QNCX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.